Tag Archives: Weight loss

Data on VIVUS’ Qnexa to be Featured at World Congress Highlighting Metabolic Disease and Related Disorders

MOUNTAIN VIEW, Calif., May 13 /PRNewswire-FirstCall/ — VIVUS, Inc. (Nasdaq: VVUS) today announced that data on Qnexa®, an investigational drug candidate, will be presented at the 3rd World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy) in Prague, Czech Republic. Timothy Garvey, … Continue reading

Posted in News | Tagged , , , , | Leave a comment

UPDATE 2-Vivus drug cuts apnea in small trial; shares jump

* Shares up 5.6 pct in premarket trading (Adds analyst comment) CHICAGO, Jan 7 (Reuters) – A small, mid-stage trial of Qnexa, an experimental weight-loss drug developed by Vivus Inc (VVUS.O), showed it reduced the incidence of sleep apnea events … Continue reading

Posted in News | Tagged , , | Leave a comment

Assessing the Chances for the Next Wave of Obesity Drugs

By ANDREW POLLACK New York Times Published: October 16, 2009 How do the three new obesity drugs stack up? So far, investors — and some doctors — are most excited about Vivus’s drug, Qnexa. Patients taking the high dose of … Continue reading

Posted in Qnexa Diet Pill | Tagged , , | Leave a comment

No Clear Winner as Top Obesity Candidates Reveal Detailed Data

By Jennifer Boggs Investors – and prospective partners – hoping that detailed data emerging from this year’s Obesity Society meeting in Washington might shed more light on the three frontrunners in the weight loss drug race came away with some … Continue reading

Posted in Qnexa Diet Pill | Tagged , , | Leave a comment

What is Qnexa? Diet Pill

Qnexa™ is a therapeutic formula and dosing regimen which combines the active ingredients from two previously approved products which demonstrated weight loss properties: phentermine and topiramate. Qnexa simultaneously addresses appetite and satiety, the two main mechanisms that impact eating behavior … Continue reading

Posted in Qnexa Diet Pill | Tagged , , | Leave a comment